1
|
Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study.
|
Circulation
|
2002
|
6.20
|
2
|
Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts.
|
Eur Heart J
|
2003
|
3.48
|
3
|
Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networks.
|
Int J Epidemiol
|
2002
|
2.48
|
4
|
Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM.
|
Eur Heart J
|
2005
|
1.78
|
5
|
PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol.
|
Clin Chem Lab Med
|
2008
|
1.42
|
6
|
Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations.
|
Am J Cardiol
|
2007
|
1.38
|
7
|
Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Münster (PROCAM) study.
|
Nutr Metab Cardiovasc Dis
|
2005
|
1.30
|
8
|
Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17.
|
PLoS Genet
|
2006
|
1.29
|
9
|
Response to Conroy et al. SCORE Project.
|
Eur Heart J
|
2003
|
1.20
|
10
|
Prevalence of cholesteryl ester storage disease.
|
Arterioscler Thromb Vasc Biol
|
2007
|
1.11
|
11
|
Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study.
|
Eur J Cardiovasc Prev Rehabil
|
2007
|
0.98
|
12
|
The impact of dietary fat composition on serum leptin concentrations in healthy nonobese men and women.
|
J Clin Endocrinol Metab
|
2002
|
0.90
|
13
|
Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation).
|
Eur J Cardiovasc Prev Rehabil
|
2006
|
0.88
|
14
|
Non-LDL-related dyslipidaemia and coronary risk: a case-control study.
|
Diab Vasc Dis Res
|
2010
|
0.86
|
15
|
Cardiovascular risk assessment in metabolic syndrome: view from PROCAM.
|
Endocrinol Metab Clin North Am
|
2004
|
0.84
|
16
|
Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease.
|
Clin Endocrinol (Oxf)
|
2004
|
0.84
|
17
|
Genes, diet and public health.
|
Genes Nutr
|
2007
|
0.83
|
18
|
The CAG repeat polymorphism in the androgen receptor gene is associated with HDL-cholesterol but not with coronary atherosclerosis or myocardial infarction.
|
Clin Chem
|
2005
|
0.82
|
19
|
Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care.
|
Curr Med Res Opin
|
2010
|
0.80
|
20
|
Relationship between phytosterol levels and components of the metabolic syndrome in the PROCAM study.
|
Eur J Cardiovasc Prev Rehabil
|
2007
|
0.79
|
21
|
Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure.
|
Clin Cardiol
|
2008
|
0.78
|
22
|
Interferences in coagulation tests--evaluation of the 570-nm method on the Dade Behring BCS analyser.
|
Clin Chem Lab Med
|
2005
|
0.78
|
23
|
Evidence for oxidative stress at elevated plasma thiol levels in chronic exposure to carbon disulfide (CS2) and coronary heart disease.
|
Nutr Metab Cardiovasc Dis
|
2006
|
0.76
|
24
|
Methods to identify increased risk of coronary disease in the general population: conclusion is oversimplification.
|
BMJ
|
2003
|
0.75
|
25
|
"Polypill" to fight cardiovascular disease: interpretation of trial data is optimistic.
|
BMJ
|
2003
|
0.75
|
26
|
Inflammation in atherosclerosis, not yet time for a paradigm shift?
|
Curr Opin Lipidol
|
2003
|
0.75
|